170 related articles for article (PubMed ID: 28188458)
1. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
Zhang T; Essani K
Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
[TBL] [Abstract][Full Text] [Related]
2. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.
Zhang T; Suryawanshi YR; Kordish DH; Woyczesczyk HM; Jeng D; Essani K
Virus Genes; 2017 Feb; 53(1):52-62. PubMed ID: 27738905
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.
Zhang T; Kordish DH; Suryawanshi YR; Eversole RR; Kohler S; Mackenzie CD; Essani K
Curr Cancer Drug Targets; 2018; 18(6):577-591. PubMed ID: 28669340
[TBL] [Abstract][Full Text] [Related]
4. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
[TBL] [Abstract][Full Text] [Related]
5. The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells.
Jeng D; Ma Z; Barrett JW; McFadden G; Loeb JA; Essani K
J Virol; 2013 Mar; 87(6):3018-26. PubMed ID: 23269801
[TBL] [Abstract][Full Text] [Related]
6. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.
Conrad SJ; El-Aswad M; Kurban E; Jeng D; Tripp BC; Nutting C; Eversole R; Mackenzie C; Essani K
J Exp Clin Cancer Res; 2015 Feb; 34(1):19. PubMed ID: 25887490
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy.
Zhang T; Suryawanshi YR; Szymczyna BR; Essani K
Med Oncol; 2017 Jul; 34(7):129. PubMed ID: 28593604
[TBL] [Abstract][Full Text] [Related]
9. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
10. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
12. Tanapoxvirus: From discovery towards oncolytic immunovirotherapy.
Suryawanshi YR; Zhang T; Razi F; Essani K
J Cancer Res Ther; 2020; 16(4):708-712. PubMed ID: 32930107
[TBL] [Abstract][Full Text] [Related]
13. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
14. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
15. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
16. [Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines].
Ammour YI; Ryabaya OO; Milovanova AV; Sidorov AV; Shohin IE; Zverev VV; Nasedkina TV
Mol Biol (Mosk); 2018; 52(4):659-666. PubMed ID: 30113031
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH
Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
Fu X; Rivera A; Tao L; Zhang X
Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
